XML 82 R44.htm IDEA: XBRL DOCUMENT
v3.20.1

Revenue - Composition of Total Revenue by Product and by U.S versus Rest of World (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | $ 164.0 | $ 216.6 | $ 545.4 | $ 635.7
U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 153.0 | 204.4 | 510.0 | 601.9
RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 11.0 | 12.2 | 35.4 | 33.8
Molecular Diagnostic - Hereditary Cancer Testing [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 85.2 | 117.6 | 307.6 | 360.7
Molecular Diagnostic - Hereditary Cancer Testing [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 81.3 | 114.3 | 295.0 | 351.4
Molecular Diagnostic - Hereditary Cancer Testing [Member] | RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 3.9 | 3.3 | 12.6 | 9.3
Molecular Diagnostic - GeneSight [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 20.4 | 29.6 | 65.6 | 82.8
Molecular Diagnostic - GeneSight [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 20.4 | 29.6 | 65.6 | 82.8
Molecular Diagnostic - Prenatal [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 20.3 | 30.6 | 60.1 | 80.0
Molecular Diagnostic - Prenatal [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 20.2 | 30.6 | 59.9 | 80.0
Molecular Diagnostic - Prenatal [Member] | RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 0.1 |  | 0.2 |
Molecular Diagnostic - Vectra [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 10.5 | 11.3 | 31.8 | 36.1
Molecular Diagnostic - Vectra [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 10.5 | 11.3 | 31.8 | 36.1
Molecular Diagnostic - Prolaris [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 6.8 | 6.9 | 20.1 | 19.2
Molecular Diagnostic - Prolaris [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 6.8 | 6.9 | 20.0 | 19.1
Molecular Diagnostic - Prolaris [Member] | RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue |  |  | 0.1 | 0.1
Molecular Diagnostic - EndoPredict [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 3.5 | 2.8 | 8.3 | 7.4
Molecular Diagnostic - EndoPredict [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 0.6 | 0.5 | 1.5 | 1.2
Molecular Diagnostic - EndoPredict [Member] | RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 2.9 | 2.3 | 6.8 | 6.2
Molecular Diagnostic - Other [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 3.8 | 1.7 | 10.1 | 6.3
Molecular Diagnostic - Other [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 3.6 | 1.5 | 9.9 | 5.8
Molecular Diagnostic - Other [Member] | RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 0.2 | 0.2 | 0.2 | 0.5
Molecular Diagnostic Testing [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 150.5 | 200.5 | 503.6 | 592.5
Molecular Diagnostic Testing [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 143.4 | 194.7 | 483.7 | 576.4
Molecular Diagnostic Testing [Member] | RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 7.1 | 5.8 | 19.9 | 16.1
Pharmaceutical and Clinical Services [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 13.5 | 16.1 | 41.8 | 43.2
Pharmaceutical and Clinical Services [Member] | U.S. [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | 9.6 | 9.7 | 26.3 | 25.5
Pharmaceutical and Clinical Services [Member] | RoW [Member] |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |
Total revenue | $ 3.9 | $ 6.4 | $ 15.5 | $ 17.7

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticGenesightTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticVectraTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticProlarisTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticEndoPredictTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |